Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug SGR-1505 enters early human testing for blood cancers

NCT ID NCT05544019

Disease control Sponsor: Schrödinger, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the drug alone, and researchers will monitor their health closely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 98 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy. * Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy ≥ 12 weeks. Exclusion Criteria: * The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit). * Subject has previous invasive malignancy in the last 2 years. * Subject has a known allergy to SGR-1505 or excipients of SGR-1505. * Subject has symptomatic or active CNS involvement of disease. * Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK-positive large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ALK-positive large B-cell lymphoma B-cell chronic lymphocytic leukemia Burkitt lymphoma diffuse large B-cell lymphoma diffuse large B-cell lymphoma germinal center B-cell type Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly follicular lymphoma high grade B-cell lymphoma hypertrophic pyloric stenosis Lymphoma, B-Cell, Marginal Zone lymphoplasmacytic lymphoma MALT lymphoma mantle cell lymphoma neoplasm of mature B-cells nodal marginal zone B-cell lymphoma non-Hodgkin lymphoma plasmablastic lymphoma primary cutaneous diffuse large B-cell lymphoma, Leg type primary cutaneous follicle center lymphoma primary effusion lymphoma primary mediastinal large B-cell lymphoma splenic marginal zone lymphoma T-cell/histiocyte rich large B cell lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK-positive large B-cell lymphoma Burkitt lymphoma Chronic lymphocytic leukemia DLBCL DLBCL germinal center B-cell type Duodenal-type follicular lymphoma EBV-positive DLBCL, nos Follicular lymphoma HHV8-positive DLBCL, nos High-grade B-cell lymphoma IRF4 gene rearrangement Lymphoplasmacytic lymphoma Malt lymphoma Mantle cell lymphoma Mature B-cell neoplasm Nodal marginal zone lymphoma Non-Hodgkin lymphoma Pediatric-type follicular lymphoma Plasmablastic lymphoma Primary cutaneous diffuse large B-cell lymphoma Primary cutaneous follicle center lymphoma Primary effusion lymphoma Primary mediastinal large B-cell lymphoma Splenic marginal zone lymphoma T-cell/histiocyte rich lymphoma Waldenstrom macroglobulinemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    36 sites in 8 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AOU Citta della Salute e della Scienza di Torino - Ospedale le Molinette

    RECRUITING

    Torino, Italy

  • AP-HP Hôpital Henri-Mondor

    RECRUITING

    Créteil, France

  • ARENSIA Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti

    RECRUITING

    Bucharest, Romania

  • ARENSIA Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca

    RECRUITING

    Cluj-Napoca, Romania

  • ARENSIA Research Clinic at Harmony Health Clinic

    RECRUITING

    Kyiv, Ukraine

  • ASST Grande Ospedale Metropolitano Niguarda

    RECRUITING

    Milan, Italy

  • Azienda Ospedaliera - Universitaria Integrata di Verona - Ospedale Borgo Roma

    RECRUITING

    Verona, Italy

  • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo - Presidio Ospedaliero SS Antonio e Biagio e Cesare Arrigo, Ospedale Civile

    RECRUITING

    Alessandria, Italy

  • Banner Health - MD Anderson Cancer Center

    RECRUITING

    Gilbert, Arizona, 85234, United States

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Email: •••••@•••••

  • Christiana Care Hospital - Helen F Graham Cancer Center

    RECRUITING

    Newark, Delaware, 19713, United States

  • Clinica Universidad de Navarra - Pamplona

    RECRUITING

    Pamplona, Spain

  • Duke University

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • Gabrail Cancer & Research Center

    RECRUITING

    Canton, Ohio, 44718, United States

  • Hospital Clinico Universitario de Salamanca

    RECRUITING

    Salamanca, Spain

  • Hospital Universitario Quironsalud Madrid

    RECRUITING

    Madrid, Spain

  • IRCCS Ospedale San Raffaele

    RECRUITING

    Milan, Italy

  • Institut Catala d'Oncologia - L'Hospitalet

    RECRUITING

    Barcelona, Spain

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, France

  • Institute of Oncology, ARENSIA Exploratory Medicine

    RECRUITING

    Chisinau, Moldova

  • Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10467, United States

  • Napa Research

    RECRUITING

    Pompano Beach, Florida, 99064, United States

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie

    RECRUITING

    Warsaw, Poland

  • Oregon Health and Science University - Knight Cancer Institute

    RECRUITING

    Portland, Oregon, 97329, United States

  • Regional Cancer Care Associates

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Rhode Island Hospital

    RECRUITING

    Providence, Rhode Island, 02903, United States

  • Roswell Park Comprehensive Cancer Center

    RECRUITING

    Buffalo, New York, 14203, United States

  • START Madrid - CIOCC

    RECRUITING

    Madrid, Spain

  • START Madrid - Hospital Fundacion Jimenez Diaz

    RECRUITING

    Madrid, Spain

  • The Ohio State University - The James Cancer Hospital

    RECRUITING

    Columbus, Ohio, 43210, United States

  • University of Texas Southwestern

    RECRUITING

    Dallas, Texas, 75390, United States

  • Uniwersyteckie Centrum Kliniczne, Osrodek Badan Klinicznych Wczesnych Faz

    RECRUITING

    Gdansk, Poland

  • Weill Cornell

    RECRUITING

    New York, New York, 10065, United States

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi

    RECRUITING

    Lodz, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.